^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Vall d'Hebron Institute of Oncology

    i
    Other names: Vall d'Hebron Institute of Oncology | VHIO | VHIO Vall d'Hebron Institute of Oncology | Vall d'Hebron Institute of Oncology (VHIO) | Vall d'Hebron Institute of Oncology (V.H.I.O.) | VHIO - Vall d'Hebron Institute of Oncology
    Related tests:
    Evidence
    News
    17d
    SERPENTINE: Single cEll pRofiling PErsistaNce To ImmuNothErapy (clinicaltrials.gov)
    P2 | N=60 | Recruiting | Sponsor: Vall d'Hebron Institute of Oncology | Trial completion date: Dec 2025 ➔ Jul 2032 | Trial primary completion date: Sep 2025 ➔ Jul 2032
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    2years
    BRAVE: Combination Therapy for BRAF-V600E Metastatic CRCm (clinicaltrials.gov)
    P2 | N=94 | Not yet recruiting | Sponsor: Vall d'Hebron Institute of Oncology
    New P2 trial • Combination therapy
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Braftovi (encorafenib)